Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod
Anat Achiron, Mathilda Mandel, Michael Gurevich, Sapir Dreyer-Alster, David Magalashvili, Polina Sonis, Mark Dolev, Shay Menascu, Gil Harari, Shlomo Flechter, Rina Falb
Topics & Concepts
FingolimodMedicineDiscontinuationImmunologyImmune systemNatalizumabMultiple sclerosisVaccinationCellular immunityInternal medicineMultiple Sclerosis Research StudiesPeripheral Neuropathies and DisordersLong-Term Effects of COVID-19